Optimal end points for acute stroke therapy trials: best ways to measure treatment effects of drugs and devices.
about
Novel methodologic approaches to phase I, II, and III trialsThe effect of covariate adjustment for baseline severity in acute stroke clinical trials with responder analysis outcomes.A collaborative sequential meta-analysis of individual patient data from randomized trials of endovascular therapy and tPA vs. tPA alone for acute ischemic stroke: ThRombEctomy And tPA (TREAT) analysis: statistical analysis plan for a sequential metImportance of proper patient selection and endpoint selection in evaluation of new therapies in acute stroke: further analysis of the SENTIS trial.Managing competing demands in the implementation of response-adaptive randomization in a large multicenter phase III acute stroke trial.How baseline severity affects efficacy and safety outcomes in acute ischemic stroke intervention trials.Effect of weekend admission on in-hospital mortality and functional outcomes for patients with acute subarachnoid haemorrhage (SAH)Quantification of errors in ordinal outcome scales using shannon entropy: effect on sample size calculations.Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis.Ideal cardiovascular health predicts functional status independently of vascular events: the Northern Manhattan Study.Head Position in Stroke Trial (HeadPoST)--sitting-up vs lying-flat positioning of patients with acute stroke: study protocol for a cluster randomised controlled trialEffect Size Estimates for the ESCAPE Trial: Proportional Odds Regression Versus Other Statistical Methods.Adopting a Patient-Centered Approach to Primary Outcome Analysis of Acute Stroke Trials Using a Utility-Weighted Modified Rankin ScaleTime to endovascular reperfusion and degree of disability in acute stroke.Identifying implications of thrombolysis for stroke rehabilitation: knowledge gaps in current research.Optimising outcome assessment to improve quality and efficiency of stroke trials.Association Between Serum Tumor Necrosis Factor Receptor 1 and Trajectories of Functional Status: The Northern Manhattan Study.C-reactive protein is associated with disability independently of vascular events: the Northern Manhattan Study.Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials.Future trials of endovascular mechanical recanalisation therapy in acute ischemic stroke patients - a position paper endorsed by ESMINT and ESNR : part II: methodology of future trials.Future trials of endovascular mechanical recanalisation therapy in acute ischemic stroke patients: a position paper endorsed by ESMINT and ESNR : part I: Current situation and major research questions.Baseline collateral status and infarct topography in post-ischaemic perilesional hyperperfusion: An arterial spin labelling study.Ginsenoside Rd Is Efficacious Against Acute Ischemic Stroke by Suppressing Microglial Proteasome-Mediated Inflammation.Differential Effect of Left vs. Right White Matter Hyperintensity Burden on Functional Decline: The Northern Manhattan Study.The Impact of Homocysteine, Vitamin B12, and Vitamin D Levels on Functional Outcome after First-Ever Ischaemic Stroke.Comparison of multistate Markov modeling with contemporary outcomes in a reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.Exploration of time-course combinations of outcome scales for use in a global test of stroke recovery.Assessing type I error and power of multistate Markov models for panel data-A simulation study.Functional Trajectories, Cognition, and Subclinical Cerebrovascular Disease.Endovascular treatment for Small Core and Anterior circulation Proximal occlusion with Emphasis on minimizing CT to recanalization times (ESCAPE) trial: methodology.Periventricular White Matter Hyperintensities and Functional Decline.Cerebral white matter disease and functional decline in older adults from the Northern Manhattan Study: A longitudinal cohort study.Utility-Weighted Modified Rankin Scale as Primary Outcome in Stroke Trials: A Simulation Study.The distribution of the modified Rankin scale scores change according to eligibility criteria in acute ischemic stroke trials: A consideration for sample size calculations when using ordinal regression analysis.Diagnosing and Treating Sleep Apnea in Patients With Acute Cerebrovascular Disease
P2860
Q27012934-125A831F-76EA-42F2-8929-2F812129AE26Q30416378-0A35668D-F9B8-4473-ABA0-A8C2EE003109Q30992330-9DD6A3AB-E5B0-4EC6-81CE-93CB84C983BAQ34143633-E8CFE8C1-BC27-4221-A06F-F6D82C7F4278Q34156578-8C9A12F3-7737-4363-96D8-A95DDBFBEA6FQ34418517-1BBFA4DF-3E2C-4C6E-94CB-E31F36FCA334Q34516272-557AA1C7-E98C-4B7E-87A6-145FE4CF0519Q34826078-5C674AAE-13DA-4732-A3C9-187B073D9C0FQ35019813-9262A67F-D7A3-492B-9754-B26B757F5A7FQ35135673-C8FA2BFA-D7DA-42E5-9B23-8F468742532EQ35700659-9BF7EA85-FF4D-423F-BAFA-1BFD77A2DE96Q35778707-2E150EA2-5AFA-40C8-BBF1-D23303E1FBEEQ35901029-D3AD3317-DA98-4B3E-BC61-163F199A4E79Q37114020-DA84E031-E876-45FD-BF21-846FA4839A55Q38051668-F9498109-E96B-40F1-B9E6-6D7A1917127DQ38172294-F10FD0A3-7D04-4163-85D8-3F032BBEDDBDQ38403465-824C077F-2C72-425F-8DB1-10BB51BC9357Q38405928-8EBC81E3-1B59-4975-82A9-EF4C30F01E9EQ38669629-425A0B00-D437-441B-B6A5-93A13F083E7AQ39558458-B50A901E-1605-47C8-8A96-BF5B43D08D81Q39558464-2A46A49A-AD0D-4663-A457-3F5F94119AEDQ40721685-F2C3ED07-6460-42D0-A529-DB018A65D3F3Q40829827-855F27EA-CB5F-41F9-88A4-35BA448ACCE7Q41917278-A12DB75E-84B1-4752-A02B-9D935823DC80Q42366203-7FE53F6A-89FB-4C91-AE72-165A04510199Q44671895-C00CA01C-979E-407B-926E-0DE7FDB6B3E5Q46201118-880C632B-D8DD-4256-B040-2EAAB4CD22E9Q47139077-C60E73CD-9F8D-4F3A-921C-DFE7E3880C78Q47551468-CDE8EFD1-957A-46AE-B0BE-E5226A94C25DQ47571021-EF85AD11-6EFE-496C-AD38-D1AF1242EE8CQ47604281-B4ED25E3-78D9-416D-A0AB-BB9AF23888DEQ52382194-0AD61632-CB59-4ED7-B797-9A597FE3EB57Q52657348-BF0FF5E5-8242-4A0D-AF06-C123C4C4B547Q55119202-BD279C17-B519-41F8-9B62-307818B495F4Q58129743-EC3B782D-2BF4-4846-815B-00C6F536EDA9
P2860
Optimal end points for acute stroke therapy trials: best ways to measure treatment effects of drugs and devices.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Optimal end points for acute s ...... effects of drugs and devices.
@ast
Optimal end points for acute s ...... effects of drugs and devices.
@en
type
label
Optimal end points for acute s ...... effects of drugs and devices.
@ast
Optimal end points for acute s ...... effects of drugs and devices.
@en
prefLabel
Optimal end points for acute s ...... effects of drugs and devices.
@ast
Optimal end points for acute s ...... effects of drugs and devices.
@en
P2860
P1433
P1476
Optimal end points for acute s ...... effects of drugs and devices.
@en
P2093
Jeffrey L Saver
P2860
P304
P356
10.1161/STROKEAHA.111.619122
P407
P577
2011-06-30T00:00:00Z